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The Effect of Platelet-Rich Plasma In Vitro
on Primary Cells: Rat Osteoblast-like Cells
and Human Endothelial Cells
Robert E.C.M. Mooren, M.D., D.M.D.,1,* Eef J. Hendriks, Medical Student,2,*
Jeroen J.J.P. van den Beucken, Ph.D.,2 Mathijs A.W. Merkx, M.D., D.M.D., Ph.D.,1
Gert J. Meijer, D.M.D., Ph.D.,1,2 John A. Jansen, D.M.D., Ph.D.,2
and Paul J.W. Stoelinga, M.D., D.M.D., Ph.D.1
The aim of this study was to evaluate the effects of standardized platelet-rich plasma (PRP) concentrates from 10
human donors on cellular behavior. The standardized PRPs used were fivefold average and fivefold maximum
baseline values in whole blood. Both these standardized PRPs were characterized by determining platelet
numbers and subsequently growth factor concentrations in activated PRPs, called PRP derivatives. Platelet
numbers in both types of standardized PRPs were significantly increased compared with whole blood. Further,
both PRP derivatives contained significantly higher concentrations of platelet-derived growth factor-AA,
platelet-derived growth factor-AB, and transforming growth factor-beta 1. Vascular endothelial growth factor
concentrations were significantly elevated in only the most concentrated PRP derivative. Cell culture experi-
ments with osteoblast-like cells showed that both PRP derivatives stimulated cell proliferation without inducing
cell differentiation, whereas tube formation in endothelial cell cultures was significantly increased by adding low
volume percentages of PRP derivative (2%–8%). Consequently, it can be concluded that there is no direct
relationship between the number of platelets and the level of growth factors released from these platelets. PRP
derivatives have the potency to stimulate angiogenesis dose dependently, while lacking the capacity to induce
osteogenic differentiation. Yet, the proliferation of osteoblast-like cells can significantly be enhanced by sup-
plementation of PRP derivatives.
Introduction
Growth factors released by activated platelets aresupposed to have a stimulating effect on several kinds
of cells involved in initial bone (wound) healing, for
example, osteoblasts, endothelial cells, fibroblasts, and mes-
enchymal stem cells. The basic hypothesis of adding platelet-
rich plasma (PRP) to bone grafts is that high concentrations
of the released growth factors enhance the initial wound
healing response.1–3
After the introduction of PRP as a strategy to enhance bone
healing, several clinical and experimental studies have been
carried out. Some of the clinical studies reported good results
when PRP was added to an autogenous bone graft.4–7 In all
these studies, human PRP was used in variable concentra-
tions. To test the validity of the addition of PRP to bone grafts,
many experimental animal studies have been carried out, but
the results of these studies are not consistent and contradic-
tory outcomes have been reported.8–17 A minority of these
studies showed a beneficial effect of PRP on the healing of
bone defect.10,14,17 These results are certainly difficult to ex-
plain, particularly in the light of the mainly positive results of
a large number of in vitro studies. To the best of our knowl-
edge, 38 in vitro studies on the use of PRP have been pub-
lished over the last 8 years. Of these 38 studies, 31 (81.5%) (24
with human PRP and 7 with animal PRP) reported significant
positive effects of PRP on the proliferation rate of osteoblasts
or osteoblast-like cells and mesenchymal stem cells.1,18–47 In
seven of these studies, a significant increase of the prolifera-
tion rate was observed when PRPwas used in a relatively low
concentration (range: 12109 to 280109 L1). It was ob-
served that higher concentrations of PRP caused a decrease
in cell proliferation.23,26,28,33,34,41,46 Slapnicka et al.48 tested
eight different concentrations of PRP (range: 0.38–2.86 times
the baseline value) and found no significant positive effect
on the proliferation rate of human osteoblasts. In eight
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studies,20,27,30–32,34,44,45 differentiation of the various cell
types used was noted, but six other studies did not reveal any
differentiation.21,36,39,40,43,47 In the studies mentioned, how-
ever, different experimental setups were used, that is, varia-
tion in cell origin, seeding density, temporal sampling, PRP
preparation procedures, and platelet concentrations. Com-
parisons are, therefore, difficult to make and conclusions are
impossible to draw. In addition, most studies draw conclu-
sions from average PRP concentrations that were retrospec-
tively calculated from the average baseline values. This is a
meaningless exercise because there are variations in the
baseline values and PRP concentrations. This effect can be
enhanced by potential dose-dependent effects of PRP and its
growth factors, which may vary for different animal species
and even individual animals/humans.
To more precisely determine the efficacy of PRP, an in vitro
study was designed to assess the effect of two concentrations
of human PRP: one based on the average baseline platelet
number and one on the maximum baseline platelet number.
The target cells were rat osteoblast-like cells and human
endothelial cells. Various osteogenic and angiogenic assays
were performed with standardized PRP derivatives. The
hypothesis was threefold:
 The concentration of growth factors increases with an
increase of platelet number.
 Platelet concentrations of fivefold the average baseline
value or fivefold maximum baseline value both affect
target cell behavior.
 A platelet concentration of fivefold the maximum
baseline value has a more profound effect on target cell
behavior than a fivefold average baseline value.
Materials and Methods
PRP preparation
Human whole blood from 10 healthy male individuals
was collected in sterile tubes with acid-citrate dextrose-A as
an anticoagulant and platelet concentrates were prepared for
clinical use by the Sanquin Blood Bank, Nijmegen, The
Netherlands. The whole blood donated was processed, sep-
arating platelets from red blood cells and leucocytes by
means of cytapheresis. Informed consent was obtained from
all individuals to use the remnants of these platelet concen-
trates for the current in vitro study. By centrifugation and
subsequent dilution, using the remnants of the platelet con-
centrates, from each donor two different PRPs were pre-
pared, both representing a different (standard) concentration
of platelets. Both PRPs were obtained independent of the
individual baseline value of platelets. For the first PRP
(PRPlow), it was the goal to achieve a platelet concentration of
*1175109 L1, which is approximately five times the av-
erage number of platelets in peripheral human blood. For the
second PRP (PRPhigh), it was the goal to achieve a platelet
concentration of *1750109 L1, which is approximately
five times the maximum number of platelets in peripheral
human blood. The platelet numbers in the PRPs and in
whole blood were counted automatically by a hematology
analyzer (ADVIA120; Siemens Healthcare Diagnostics). The
PRPs and whole blood were then activated by adding cal-
cium chloride and Fibriquik (Thrombin Reagent; bioMer-
ieux, Inc.) to the blood product in the ratio 1:1:6 (v/v/v),
following the manufacturer’s protocol. Clots were allowed
to retract for 30min. After that, a centrifugation step was
carried out at 4000 rpm for 10min at 228C to separate the
supernatant, containing the growth factors, from the aggre-
gated platelets. The supernatants were stored at 808C. The
supernatant of both PRPs was called PRP-derivativelow and
PRP-derivativehigh, respectively.
Determination of growth factor levels
Samples of all 10 donors (whole blood and prepared PRP
derivatives) were subjected to enzyme-linked immunosor-
bent assays (ELISAs; Quantikine; R&D Systems Europe
Ltd.) for measuring the amount of human platelet-derived
growth factor (PDGF)-AA, PDGF-AB, PDGF-BB, transform-
ing growth factor-beta 1 (TGF-b1), insulin-like growth factor-
I (IGF-I), and vascular endothelial growth factor (VEGF). The
immunoassays were performed following the manufactur-
er’s instructions and the minimal detectable dose of these
growth factors with the used ELISA test were PDGF-AA
2.29 pg/mL, PDGF-AB 1.7 pg/mL, PDGF-BB <15 pg/mL,
TGF-b1 4.61 pg/mL, IGF-I 0.026 ng/mL, and VEGF <9.0 pg/
mL. All samples were analyzed in duplicate, after which the
absorbance was measured at 450 nm (EL800 Universal
Microplate Reader; Bio-Tek Instrument, Inc.).
Osteoblast-like cell culture experiment
Cell isolation and culture. Rat bone marrow cells were
isolated and cultured using the method described by Man-
iatopoulos et al.49 Briefly, the two femora of a male Wistar rat
(40–43 days old) were retrieved and washed in wash me-
dium (a-modified Eagle’s medium [a-MEM]; Gibco BRL, Life
Technologies B.V. Breda) supplemented with 0.5mg/mL
gentamycin and 3 mg/mL fungizone (Sigma-Aldrich).
Epiphyses were cut off and diaphyses were flushed with
10mL of osteogenic medium (a-MEM, supplemented with
10% fetal calf serum [Gibco BRL, Life Technologies B.V.
Breda], 50mg/mL ascorbic acid [Sigma-Aldrich], 10mM b-
glycerophosphate, 108 M dexamethasone [Sigma-Aldrich],
and 50 mg/mL gentamycin). The isolated cells were cultured
in osteogenic medium in three 75 cm2 culture flasks (Greiner
Bio-one GmbH) in a humidified atmosphere of 95% air and
5% CO2 at 378C (IG 650/750; JOUAN S.A.). The osteogenic
medium was changed every 2 or 3 days. After 7 days of
preculture, the obtained osteoblast-like cells were used for
the cell culture experiments, which was carried out in two
independent runs in triplicate (n¼ 3). For each run, freshly
isolated cells were used.
Cell seeding. After 7 days of primary culture in osteo-
genic medium, the osteoblast-like cells were trypsinized,
harvested, counted, and finally seeded in 24-well plates at a
concentration of 10,000 cells/cm2. Four experimental condi-
tions were created:
1. Negative control (basic medium: a-MEMþ 10% fetal
calf serumþ gentamycin);
2. PRP-derivativelow (basic medium enriched with PRP-
derivativelow);
3. PRP-derivativehigh (basic medium enriched with PRP-
derivativehigh);
4. Positive control (osteogenic medium).
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The PRP derivatives used in the cell culture experiment
consisted of volumetrically pooled PRP derivatives of the in-
dividual donors to assure sufficient volumes for stimulation in
the cell culture experiments. Addition of PRP derivatives was
carried out at days 1, 4, and 7 after cell seeding by adding
10vol% (v/v) of the respective PRP derivative to basic me-
dium. This procedure allows potential stimulation of the cells
by the PRP derivatives for a period of up to 10 days. Cells were
cultured in a humidified atmosphere of 95% air and 5%CO2 at
378C, with three medium refreshments per week.
Cell proliferation. Cell proliferation was measured by
determination of cellular protein content in individual wells
(n¼ 3) for each experimental group. At 4, 8, 12, 16, and 24
days postseeding, the medium was removed and the cells
were washed with phosphate-buffered saline (PBS; pH 7.4).
Subsequently, 1mL milliQ was added. Samples were frozen
and thawed for three repetitive cycles, after which the cel-
lular protein content was determined using a micro bi-
cinchoninic acid (BCA) protein assay (Pierce) according to
the instructions of the manufacturer.
Alkaline phosphatase analysis. Alkaline phosphatase
(ALP) activity was measured as a marker for early differ-
entiation of osteoblast-like cells using the same samples
(n¼ 3) as for the proliferation assay according to a previously
described method.50 A volume of 80 mL of sample or stan-
dard and 20 mL of buffer solution (5mM MgCl2, 0.5M
2-amino-2-methyl-1-propanol) was pipetted into a 96-well
plate (Greiner Bio-One) in duplicate and 100mL of substrate
solution (5mM paranitrophenylphosphate) was added to
each well. Subsequently, the plate was incubated for 1 h at
378C, after which the reaction was stopped by adding 100mL
of 0.3M NaOH. Serial dilutions of 4-nitrophenol (final con-
centrations: 0–25 nM) were used for the standard curve. The
plate was read in an ELISA reader at 405 nm.
Calcium content. The deposition of calcium was used as
a marker of late differentiation of osteoblast-like cells. The
amount of calcium deposited after 4, 8, 12, 16, and 24 days of
cell culture was measured by the orthocresolphthalein com-
plexone (OCPC) method (Sigma), as described previously.51
Briefly, the cells were washed twice using PBS, after which
1mL of 0.5N acetic acid was added to each of three wells per
experimental group (n¼ 3). After overnight incubation on a
shaking apparatus, 300mL working solution was added to
10 mL sample of standard in a 96-well plate (Greiner).
Working solution consisted of (a) OCPC solution (80mg
OCPC in 75mL milliQþ 0.5mL of 1M KOHþ 0.5mL of
0.5N acetic acid), (b) 14.8M ethanolamine/boric acid buffer
(pH 11), (c) 8-hydroxyquinoline (1 g in 20mL of 95% etha-
nol), and (d) milliQ, in a ratio of 5:5:2:88 (a:b:c:d). A standard
curve was generated by preparing serial dilutions of CaCl2
(range: 0–100mg/mL).
Morphological analysis. Scanning electron microscopy
(SEM) was used to analyze cell morphology. For this pur-
pose, cells were seeded on Thermanox coverslips (13mm
diameter [dia]) in 24-well plates. Samples (n¼ 2) were pre-
pared after 4 and 16 days of cell culture by washing twice
with PBS, incubation in glutaraldehyde (2%) for 10min,
washing with 0.1M cacodylate buffer, and incubation in a
graded series of ethanol for dehydration. Finally, the samples
were dried with tetramethylsilane (ACROS organics), sput-
ter-coated with gold, and analyzed using a JEOL 6310 SEM.
Endothelial cell culture experiment
Culture of endothelial cells. Human umbilical vein en-
dothelial cells (HUVECs) were obtained cryopreserved from
BD Biosciences (BD Biosciences Discovery Labware).
Cells were cultured in 75 cm2 culture flasks in Medium-200
(Cascade Biologics) supplemented with low serum growth
factors (containing 1mg/mL hydrocortisone, 1.5 mg/mL ba-
sic fibroblast growth factor, 5mg/mL heparin, 100mg/mL
bovine serum albumin, gentamycin/amphotericin B, 5mg/
mL epidermal growth factor, and 2% fetal bovine serum) and
incubated in a humidified atmosphere of 95% air and 5%
CO2 at 378C until 80% confluence.
Tube-formation assay. The effect of various dilutions of
the PRP derivates on the tube-formation capacity of HUVECs
(BD Biosciences Discovery Labware) was studied using a
commercially available tube-formation assay (BD BioCoat
Angiogenesis Plates, 96-well format; BDBiosciencesDiscovery
Labware) and HUVECs of passage 2 or 3. The assay was
performed following manufacturer’s instructions (Guidelines
for Use, BD BioCoat Angiogenesis System Endothelial Cell
Tube Formation, Version 3.0), except for the staining and
measuring. HUVECs were seeded at 20103 cells/well, and
the experimental conditions enrolled in the tube-formation
assay consisted of increasing volume % of pooled PRP deriv-
atives. On the basis of the results of a preliminary experiment
with range 5%–50% (v/v), which revealed a significant de-
crease of tube formation when the volume % was >20%, a
range of 2%–20% was used to obtain more detailed informa-
tion about the most effective concentration(s). The positive
control consisted of VEGF-supplementedmedium (20ng/mL;
recombinant rat VEGF, rrVEGF164; Department of Biochem-
istry, Radboud University Nijmegen Medical Centre, Nijme-
gen, The Netherlands). The plates were incubated in a
humidified atmosphere of 95% air and 5% CO2 at 378C for
18h. Following incubation, the medium was carefully re-
moved from the plates and the plates were washed twice with
Hank’s balanced salt solution containing CaCl2 and MgCl2
(Gibco, Invitrogen) by adding 100mL of this solution to
each well. Subsequently, digital images were made of each
well using a Leica DC-200 digital camera (LEICA Microscopy
Systems Ltd.) mounted on a Leica Leitz DM IL microscope
(Leica Mikroskopie & Systeme GmbH) at a magnification of
40(Leica 519 750 Periplan 10/18 and Leitz Wetzlar 519759
EF 4/0.12). Images were analyzed manually with Leica QWin
software (Leica Microsystems) for the parameters ‘‘total tube
length’’ and ‘‘number of connections.’’ The tube-formation
assay was carried out with at least five samples per experi-
mental group (n¼ 5).
Statistical analysis
Results of the platelet count and cell culture experiment
were statistically evaluated using one-way analysis of
variance, followed by post-hoc Tukey–Kramer multiple
comparisons test. Results of the tube-formation assay were
statistically evaluated, using one-way analysis of variance,
followed by post-hoc Dunnett multiple comparisons test. The
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significance level for both tests was set at p< 0.05. Calcula-
tions were performed in GraphPad Instat, Version 3.05
(GraphPad Software).
Results
PRP characterization
Platelet counts. Platelet counts of whole blood and both
PRPs of each individual donor are depicted in Table 1. Pla-
telet counts in whole blood ranged from 116 to 462109 L1,
with an average of 236 98109 L1. Platelet counts of both
PRPs were significantly higher compared with whole blood
( p< 0.001): PRPlow averaged 1181 104109 L1 (range:
971–1351109 L1); PRPhigh averaged 1879 125109 L1
(range: 1780–2072109 L1). Platelet counts in PRPhigh were
also significantly higher compared with PRPlow ( p< 0.001).
Growth factor levels. Levels of various growth factors
(PDGF-AA, PDGF-AB, PDGF-BB, TGF-b1, IGF-I, and VEGF)
were measured using ELISA. The mean growth factor levels
(averaged from the levels of each individual donor) in whole
blood and both PRP derivatives are presented in Figure 1. All
measurements were above the detection limits.
Significant differences were observed for both PRP deriv-
atives compared with whole blood for PDGF-AA (PRP-
derivativelow: p< 0.01; PRP-derivativehigh: p< 0.001), PDGF-AB
( p< 0.01), and TGF-b1 ( p< 0.001). Additionally, PRP-
derivativehigh showed significantly higher levels of VEGF
compared with whole blood ( p< 0.01). For PDGF-BB and
IGF-I, no statistically significant differences were measured
between the three different groups ( p> 0.05). No significant
differences were observed between both PRP derivatives.
Cell culture experiment—osteoblast-like cells
Two separate runs of the cell culture experiment with
primary osteoblast-like cells were carried out, which showed
similar results for proliferation, differentiation, mineraliza-
tion, and morphology. The details of one representative run
are presented below.
Proliferation. Total cellular protein levels were measured
after 4, 8, 12, 16 and 24 days of culture (Fig. 2). Compared
with the positive controls, PRP-derivative supplementation
significantly increased cell proliferation at day 12 ( p< 0.001),
day 16 (PRP-derivativelow: p< 0.05; PRP-derivativehigh:
p< 0.01), and day 24 ( p< 0.001). In contrast, negative con-
trols showed significantly decreased cell proliferation at day
8 ( p< 0.001) and significantly increased cell proliferation at
day 24 ( p< 0.001) compared with positive controls.
Differentiation. ALP activity was measured as a marker
for osteoblast-like cell differentiation (Fig. 3). Compared with
positive controls, PRP-derivative supplementation signifi-
cantly decreased ALP activity at day 12 ( p< 0.001) and day
24 (PRP-derivativelow: p< 0.01; PRP-derivativehigh: p< 0.001).
Negative controls showed significantly decreased ALP ac-
tivity at day 24 ( p< 0.01) compared with positive controls.
Mineralization. The deposition of calcium in the miner-
alized extracellular matrix by primary rat osteoblast-like cells
was used as a late marker of differentiation (Fig. 4). Com-
pared with positive controls, PRP-derivative supplementa-
tion significantly decreased mineralization at day 16
( p< 0.01) and day 24 ( p< 0.001). Additionally, negative
controls showed significantly decreased mineralization at
day 16 ( p< 0.01) and day 24 ( p< 0.001) compared with
positive controls.
Morphology analysis. After 4 and 16 days, the morpho-
logical appearance of the different experimental cell cultures
were analyzed using SEM. At day 4, no calcium deposition
could be seen for all groups. Osteoblast-like cells were cov-
ering parts of the surface. At day 16, calcium deposition
could be seen in the positive control groups in the form of
mineralized nodules. Some collagen bundles were also seen
in this group. Both PRP-derivative supplemented groups
showed calcium deposition, though substantially less com-
pared with the positive control group. Moreover, no appar-
ent differences in calcium deposition could be seen between
the two PRP-derivative-supplemented groups. In the nega-
tive control group, no mineralized nodules could be
observed. Electron microscopy images from day 16 are de-
picted in Figure 5.
Cell culture experiment—endothelial cells
Primary HUVECs were cultured with supplementation
of VEGF (20 ng/mL; control) or PRP derivatives (various
volume %; range: 2%–20%). Different volumes of PRP de-
rivatives cause dilutions corresponding to different concen-
trations of platelets per experimental group PRPlow and
PRPhigh, respectively (Table 2). After 18 h of incubation, light
microscopy images were obtained (Fig. 6), which were sub-
sequently used to determine the parameters ‘‘tube length’’
and ‘‘number of connections.’’
Tube length. Compared with controls, supplementation
of 2%–8% PRP derivative significantly increased tube length
Table 1. Platelet Counts (109/L) for Each
Human Donor (n¼ 10) in Whole Blood and Both
Platelet-Rich Plasmas (Platelet-Rich Plasmalow
and Platelet-Rich Plasmahigh)
Platelet number (109 L1)
Donor Whole blood PRPlow PRPhigh
1 204 1111 1741
2 275 971 1926
3 146 1230 2072
4 203 1226 2006
5 116 1224 1833
6 223 1215 1780
7 462 1351 Unknown
8 225 1151 Unknown
9 185 1153 1796
10 316 Unknown Unknown
Mean 236 1181 1879
SD 98 104 125
Mean and standard deviation (SD) are given at the end of the
table. The mean platelet counts for the three preparations are
significantly different ( p< 0.001).
PRP, platelet-rich plasma.
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FIG. 2. Cellular protein concentrations (mg/mL) in primary rat osteoblast-like cell cultures for positive controls (osteogenic
medium), negative controls (basic medium), and PRP-derivative-supplemented media. Bars represent mean SD of triplicate
samples. *p< 0.05, **p< 0.01, and ***p< 0.001 compared with positive controls. Color images available online at www
.liebertonline.com/ten.
FIG. 1. Concentration of
growth factors (103 pg/
mL) PDGF-AA, PDGF-AB,
PDGF-BB, TGF-b1, IGF-I,
and VEGF in human PRP
derivatives. Bars represent
means SD of triplicate
samples. *p< 0.05,
**p< 0.01, and ***p< 0.001
compared with whole
blood. PDGF, platelet-
derived growth factor;
TGF-b1, transforming
growth factor-beta 1; IGF-I,
insulin-like growth factor-I;
VEGF, vascular endothelial
growth factor; PRP, plate-
let-rich plasma; SD, stan-
dard deviation. Color
images available online at
www.liebertonline.com/
ten.
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FIG. 3. ALP activity (nmol 4-NP per hour per mg cellular protein) in primary rat osteoblast-like cell cultures for positive
controls (osteogenic medium), negative controls (basic medium), and PRP-derivative-supplemented media. Bars represent
mean SD of triplicate samples. **p< 0.01 and ***p< 0.001 compared with positive controls. ALP, alkaline phosphatase.
Color images available online at www.liebertonline.com/ten.
FIG. 4. Calcium deposi-
tion (mg/mL) in primary rat
osteoblast-like cell cultures
for positive controls (osteo-
genic medium), negative
controls (basic medium),
and PRP-derivative-supple-
mented media. Bars repre-
sent mean SD of triplicate
samples. **p< 0.01 and
***p< 0.001 compared with
positive controls. Color
images available online at
www.liebert
online.com/ten.
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( p< 0.01; Fig. 7). Supplementation with higher volume %
(>15%) of PRP derivatives showed to decrease tube length
significantly ( p< 0.01).
Number of connections. Compared with controls, sup-
plementation of 2%–8%PRP derivatives significantly increased
the number of connections of HUVECs ( p< 0.01; Fig. 8).
Supplementation of HUVECswith higher amounts showed no
significant effect on the number of connections ( p> 0.05).
Discussion
The aim of this study was to evaluate the effects of two
standardized and significantly different groups of PRP from
FIG. 5. Scanning electron
micrographs of rat bone
marrow cells at day 16.
Graphs are shown for the
groups: positive controls
(A, 750; B, 4000), negative
controls (C, 750; D, 4000),
PRP-derivativelow (E, 750;
F, 4000), PRP-derivativehigh
(G, 750; H, 4000).
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10 human donors on cellular behavior. The standardized
PRPs used were fivefold average and fivefold maximum
base line values of platelets in whole blood. These stan-
dardized PRPs were defined by determining platelet num-
bers and subsequently growth factor concentrations in the
supernatant of activated PRP, called PRP derivatives. Sub-
sequently, both PRP derivatives were used as an additive in
cell culture assays using primary osteoblast-like cells or
primary endothelial cells.
The hypothesis was threefold:
 The concentration of growth factors increases with an
increase of platelet number.
 Platelet concentrations of fivefold the average baseline
value or fivefold maximum baseline value both affect
target cell behavior.
 A platelet concentration of fivefold the maximum
baseline value has a more profound effect on target cell
behavior than a fivefold average baseline value.
The results of this experiment reveal that the first and the
third of the three hypotheses have to be rejected. The growth
factors TGF-b1 and PDGF (AA and AB) in both experimental
PRP groups were significantly increased when compared
with the whole blood, but no significant difference was seen
between the two groups of PRP. The both increased con-
centrations of platelets, when compared with the whole
blood, had a positive effect on the target cells. A platelet
concentration of five times the maximum baseline value does
not have a more profound effect on the target cells than a
platelet concentration of five times the average baseline
value.
PRP characterization
From the 38 in vitro studies performed on the use of PRP in
the last 8 years, only Ishida et al.29 calculated the occurrence
of a significant difference between the platelet number in the
whole blood samples and their experimental PRP. In the
majority of the other studies, however, no reference value of
the whole blood platelet numbers was given, and therefore,
the result presented in these studies are difficult to inter-
pret.18,19,22,24,25,30–33,35,36,38,40,41,43,44,46,47,52–55 Also, in several
studies, there is a great variation in the concentrations used,
or only a mean multiplication factor has been mentioned
without specification of the concentrations used, which
makes comparisons almost meaningless.31,32,40,43,52,53
When carrying out studies on the effect of PRP, it is im-
portant that the variation of the concentration of the platelets
in the various PRP groups is minimized. Especially, overlap
of platelet concentrations of different groups of PRP and
whole blood should be avoided when groups are to be
compared. For this reason, it was the aim of the present
study to compare the effect and the amount of growth factors
of two groups of PRP, with significantly different concen-
trations of platelets between each group of PRP and whole
blood.
According to Marx,56 in human beings, a sufficient cellular
response to PRP is expected when a four- to fivefold increase
over whole blood platelet numbers is achieved. However, he
did not make it clear, whether this concerns the individual,
the average, or the maximum value of the whole blood
platelet number. For this reason, it was the purpose of the
present study to compare PRP with a four- to fivefold av-
erage (PRPlow) and a four- to fivefold maximum platelet
number (PRPhigh), independent of the individual baseline
concentration of the donors.
The results of the platelet count showed statistically sig-
nificant differences between whole blood (mean value: 236
98109 platelets/L), PRPlow (mean value: 1181 104109
platelets/L), and PRPhigh (mean value: 1879 125109
platelets/L). This implies that a concentration of fivefold
average platelet numbers (PRPlow) and a concentration of
fourfold maximum platelet numbers (PRPhigh) were ob-
tained. Unfortunately, the volume of the blood samples used
was not enough to prepare a third group of PRP with a four-
to fivefold individual baseline platelet number. This was due
to the fact that the selected donors gave blood for clinical
use and we were only allowed to use the remnants of the
prepared platelet concentrates.
Regarding the growth factor concentrations, the results of
this study showed a statistically significant difference in
the concentrations of PDGF-AA, PDGF-AB, and TGF-b1
between both PRP derivatives and whole blood. Only in
the PRP-derivativehigh group, the concentration of VEGF
showed a significant higher level when compared with
whole blood. No significant differences were observed be-
tween the levels of the growth factor concentrations of the
two PRP derivatives.
A large variation in PRP growth factor concentration has
been reported by several authors.27,32,57,58 Compared with
the present study, Kilian et al.32 reported on similar results
for TGF-b1 (PRP platelet numbers: 1021.9 345.9109 L1).
This was not the case for the level of PDGF-AB, which was
much higher (162,164 pg/mL), and the levels of PDGF-AA
(639 pg/mL) and PDGF BB (578 pg/mL) were substantially
lower than that in the present study. The level of VEGF was
found to be not detectable. Han et al.27 showed higher levels
of PDGF-AB (>100 ng/mL) and TGF-b1 (>400 ng/mL) with
Table 2. Different Volumes of Platelet-Rich
Plasma Derivatives Causes Dilution Corresponding
with Different Concentrations of Platelets
per Experimental Group
Microliters of PRP derivative
per 100mL of cell suspension
Corresponding number
of platelets (109 L1)
(volume %) PRPlow PRPhigh
2 23.5* 35*
5 58.8* 87.5*
8 94* 104*
10 117.5 175
12 141 210
15 176.3 263
18 211.5 315
20 235 350
30 352.5 525
40 470 700
50 587.5 875
Peripheral blood; mean
[platelet]
236
Positive significant results of the experimental groups PRPlow and
PRPhigh in both tube-formation assays are indicated by an asterisk.
*p< 0.01 was found for each experimental group compared with
control.
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FIG. 6. Tube-like structures are shown for the groups: control with VEGF (A, B), PRP-derivativelow 2% (C), PRP-deriva-
tivehigh 2% (D), PRP-derivativelow 5% (E), PRP-derivativehigh 5% (F), PRP-derivativelow 8% (G), PRP-derivativehigh 8% (H),
PRP-derivativelow 10% (I), and PRP-derivativehigh 10% ( J). Color images available online at www.liebertonline.com/ten.
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PRP platelet numbers of 1511109 and 1897109 L1, re-
spectively. The levels of PDGF-AA and PDGF-BB were not
measured. They reported on a dose-dependent stimulatory
effect of TGF-b1 on cell cultures. PRP with 50–100 ng/mL
TGF-b1 appeared to be an optimal concentration. In another
study by Han et al.,57 higher levels of PDGF-BB (18,000 pg/
mL) and TGF-b1 (100,000 pg/mL) in PRP have been reported
with an eightfold increase over baseline platelet value,
whereas the level of VEGF (245 pg/mL) was similar to the
present study. Unfortunately, these authors did not measure
the levels of PDGF-AA and PDGF-AB. Huang et al.58 re-
ported on higher levels of TGF-b1 (8269.67 pg/mL) and
PDGF-AB (86,449.48 pg/mL), respectively, compared with
the present study, when PRP with platelet numbers
1240109 L1 (159.72) was used. The levels of PDGF-AA
and PDGF-BB were not measured. The level of VEGF
(192 pg/mL), however, was somewhat lower than that in the
present study.
In the aforementioned studies,27,32,57,58 as well as in the
present study, human blood was collected in tubes with acid-
citrate dextrose-A as an anticoagulant and the PRP was
activated by adding a mixture of thrombin and calcium
chloride. In one study,32 calcium gluconate instead of cal-
cium chloride was used. The ratios of thrombin (bovine) and
calcium chloride in these studies were comparable, but the
amount of the added mixture to 1mL PRP varied from 100 to
300 IU/mL PRP. There was no relation between the amount
of the added mixture of thrombin and calcium chloride and
the level of growth factor measured. The ELISA kits used to
measure the levels of the growth factors were the same in all
the aforementioned studies. The number of donors who gave
blood differed: for example, 1 donor,32,57 2 donors,27 5 do-
nors,58 and 10 donors (the present study).
Apart from the number of the donors and the amount of
thrombin added, the most variable parameter in all these
studies is the variation in the concentration of the platelets
FIG. 7. Tube length (mm) of human umbilical vein endothelial cells, supplemented with VEGF (20 ng/mL; control) or PRP
derivative (various volume %; range: 2%–20%). Bars represent mean SD of at least five samples. **p< 0.01 compared with
controls. Color images available online at www.liebertonline.com/ten.
FIG. 8. Total number of connections formed by human umbilical vein endothelial cells, supplemented with VEGF (20 ng/
mL; control) or PRP derivative (various volume %; range: 2%–20%). Bars represent mean SD of at least five samples.
**p< 0.01 compared with controls. Color images available online at www.liebertonline.com/ten.
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used. Whether this fully explains the variations of the levels
of the growth factors measured, especially PDGF, remains to
be investigated.
Roussy et al.42 showed that concentrations of growth fac-
tors are time dependent and reported on different concen-
trations after 0, 1, and 24 h and 6 days. Another influence of
growth factor release is the pH of the environment. Liu
et al.33 demonstrated that a low pH of 5.0 contained the
highest PDGF concentration, but the lowest TGF-b concen-
tration. Other factors may be the number of freeze–thaw
cycles of PRP and individual differences in growth factor
release.
In the present study, a statistically significant difference in
the number of platelets between all three groups was found.
The concentration of growth factors (TGF-b1, PDGF-AA,
and AB), however, differed only between the whole blood
and each of the PRP derivatives, but not between the two
PRP derivatives. This implies that there is no direct relation
between an increase in the number of platelets and an in-
crease in the amount of the growth factors released.
Cell culture experiment—osteoblast-like cells
The present study revealed that both PRP derivatives had
a stimulatory effect on the late cell proliferation compared
with positive controls (i.e., cell culture in osteogenic medi-
um). There was, however, no significant difference between
the two types of PRP derivatives. These results are in con-
trast to studies that reported on a dose-dependent effect of
PRP on cell proliferation.1,22,25–27,29,31,33,35–37,40,41,43,44,46,52 It
needs to be emphasized, however, that comparison of the
results of these reports is difficult because of differences in
the origin of the cells and the performed experimental pro-
cedures. For instance, the used cells in these reports are either
primary cells or cell lines and were treated to form different
tissues (e.g., bone, connective tissue, periodontal ligament,
cartilage), which implies that the susceptibility for compo-
nents of the PRP is variable or even absent. Different PRP
preparation methods and donor variability are also likely to
influence growth factor levels within a PRP derivative, which
makes comparisons of its biological effects between different
experiments difficult. Also, cellular behavior commonly re-
lies on a combination of factors, which makes comparisons
for PRP derivatives with different levels of multiple growth
factors extremely unreliable. In view of the studies reporting
dose-dependent effects of PRP on cell proliferation, it needs
to be mentioned that not all reports provide detailed infor-
mation of the PRP that was added to the used cell culture
medium.25,31,35,41,43,52
Several authors describe the use of 1%–30% (v/v) PRP in
cell culture experiments with stimulatory effects on cell
proliferation.1,29,36,40 It is of interest that Weibrich et al.,46
Choi et al.,23 Pietramaggio et al.,41 and Hsu et al.28 showed
significant increase in cell proliferation when adding low
volume percentages and a decrease in cell proliferation
when adding high volume percentages of PRP. Weibrich
et al.46 and Choi et al.23 showed the highest increase in cell
proliferation at 1%–5% PRP addition. Okuda et al.39 showed
that PRP addition of 2% and 5% stimulated DNA synthesis
in gingival fibroblasts, periodontal ligament cells, osteo-
blasts, and osteoblastic ligament cells. Similarly, Hsu et al.28
measured a significant increase in proliferation of human
periodontal ligament cells on 2% and 5% PRP gel and a
significant decrease on 15% and 30% PRP gel. Considering
the results mentioned, it appears that the concentrations
used in the present study (corresponding to 107109
platelets/L for PRPlow and 159109 platelets/L for PRPhigh)
were relatively high. Yet, the observed stimulation of the
cell proliferation was obvious and similar for both PRP
derivatives.
Results of the ALP activity analysis, a marker for early
differentiation of osteoblast-like cells, showed the inability of
PRP derivatives to induce osteoblast-like cell differentiation.
These results are in keeping with the findings of Arporn-
maeklong et al.,21 Kanno et al.,1 Ogino et al.,36 van den Dolder
et al.,45 and Zaky et al.,47 who all reported on a significant
suppression of early differentiation by PRP. Some studies,
however, reported on an early increase of ALP activity of
periodontal ligament cells, osteoblasts, or adipose-derived
stroma cells, respectively, when using PRP.20,27,31,34,44
The absence of mineralized matrix deposition within the
extracellular matrix is the consequence of the lack of early
osteoblast-like cell differentiation, as seen in the present
study.
The calcium content of PRP-derivative-supplemented
cultures was found to be permanently low, whereas positive
controls (i.e., cultures in osteogenic medium) showed a
profound increase in the latest stage of the culture. The ob-
served ALP activity and calcium content are in keeping with
the presence of mineralized nodules in positive controls,
whereas these nodules were absent in PRP-derivative-
supplemented cultures. Some authors, however, reported
stimulation of early and late differentiation.30–32,44 Liu et al.34
demonstrated induction of early and late differentiation by
PRP, whereas no osteogenic medium was added to the ex-
perimental PRP groups. van den Dolder et al.45 even showed
a significant positive effect of PRP on the late differentiation
of osteoblast-like cells (i.e., significant increase in calcium
deposition after 8, 12, and 16 days), despite a negative
effect of PRP on the ALP activity at days 4, 8, and 12. The
addition of PRP in their setup, however, was different from
the one in the present study, that is, PRP coating versus PRP
derivative addition to cell culture medium. The exact reason
for this discrepancy remains unclear.
Cell culture experiment—endothelial cells
As there is hardly any information on the use of tube-
formation assays to analyze the potential angiogenic effect of
PRP, a commercially available method for screening angio-
genesis59 was used. In the present study, this method was
applied with VEGF stimulation (20 ng/mL) as a positive
control next to both PRP derivatives in different volume
percentages.
The results of the tube-formation analysis showed signif-
icant effects on tube length and number of connections for
2%, 5%, and 8% supplementation of both PRP deriva-
tives compared with positive controls. The optimal volume
percentage of PRP derivative was found to be *5% for each
PRP derivative. The actual concentrations of growth factors
in the cell medium of 5% for PRPlow or PRPhigh corresponded
with platelets numbers of *60109 and *90109 L1, re-
spectively (Table 2). Weibrich et al.46 and Choi et al.23 showed
highest increase in cell proliferation at 58.9109 platelets/L
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and 12 to 62109 platelets/L (1%–5%), respectively. In both
studies, however, different cells, that is, osteoblast-like cells
and alveolar bone cells, were used, but no endothelial cells.
At present, only two studies used PRP in combination with
endothelial cell culture (HUVECs).60,61 Fre´chette et al.60 re-
ported on a strong beneficial effect of PRP on the prolifera-
tion of human osteoblasts and endothelial cells (HUVECs).
The authors found that the supernatants, which were ob-
tained after activation of PRP by adding calcium chloride
and thrombin, appear to be more mitogenic for HUVECs
than for nonactivated PRP supernatants. In contrast, PRP
activation had little additional benefit on osteoblast prolif-
eration. The amount of calcium chloride and thrombin ad-
ded, revealed to be of influence on the proliferation, but the
authors concluded that additional experiments are needed to
determine which concentrations are optimal for bone for-
mation in vivo.
Based on the results from in vitro vasculogenesis of en-
dothelial cells, Hofmann et al.61 created a long-term coculture
model of HUVECs and primary human osteoblasts em-
ploying polyurethane and PRP in a static microenvironment.
The authors concluded that growth factors released from
PRP are likely to provide additional stimulation for growth
and maturation of HUVECs. The results of the current study
are in accordance with this conclusion, since both PRP-
derivatives showed improved tube formation compared to
VEGF alone, even within 16–18 h.
Conclusion
The results of this study reveal that there is no direct
linear relationship between the number of platelets and the
level of growth factors released from these platelets. Pro-
liferation of primary osteoblast-like cells was stimulated only
in a late phase by both PRP derivatives with relatively low
concentrations because of dilution. Both early and late dif-
ferentiations were suppressed by PRP. From the tube-
formation assays, one may conclude that a relatively low
concentration of activated platelets stimulates the prolifera-
tion of endothelial cells, but slightly higher concentrations
have already an inhibitory effect on angiogenesis. This im-
plies that there is an optimal concentration of platelets-
stimulating target cells.
Because the platelet numbers for this optimal angiogenic
effect are far beneath the physiological level in the peripheral
blood of human beings, it may be that forced ex vivo acti-
vated PRP produces a different amount of growth factors,
when compared with PRP or whole blood, activated under
physiological conditions. It may also be that the way by
which the platelets become activated ex vivo influences the
biological activity of the growth factors.62 In vivo environ-
mental factors, not present in in vitro experiments, may also
play a role in the way by which the platelets become acti-
vated and in the effect of their growth factors.
Also, one has to realize that both in vivo and in vitro added
PRP gets diluted. This cannot be measured in in vivo expe-
riments, which makes it difficult to compare the results of
both kinds of experiments.
The range of the optimal effective doses is probably rather
small and may vary from species to species and even from
individual to individual of one species. This may explain a
lot of the contradictive findings of both in vivo an in vitro
studies. The present study only assessed a four- to fivefold
platelet concentration based on an average and a maximum
value of platelets. The effect, however, of a four- to fivefold
individual baseline concentration also needs to be further
assessed. Till present, therefore, it is impossible to provide
strict recommendations for the optimal PRP concentration.
Future studies should, however, always utilize PRP with a
fixed range of platelet concentrations.
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